TICKERNERD
Menu
TWSTTWSTHealthcare · Biotechnology

TWST Stock Forecast: Twist Bioscience Corp. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$167
−18.55% on the day

The 13 Wall Street analysts covering Twist Bioscience Corp. hold a median 12-month price target of $118 — -29.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 5 Oct 2026 — in the upper half.

Market cap
$13.6B
Ticker Nerd rank
63 / 100
Median analyst target
$118
Analysts covering
13
Revenue$118.4M+23.2% y/y
Operating income−$36.3M
Net income−$35.1M
Free cash flow−$8.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.3%
1M
+33.9%
YTD
+426.4%
1Y
+424.2%
From 52W high
−18.6%
From 52W low
+556.1%
$25
$205
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TWST stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Twist Bioscience Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Oct 2026
63 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Quality
80
Revisions
66
Value
62
Accruals
61
Growth
53
Issuance
29
Volatility
28
Size
13

Momentum (100): The shares have been drifting up relative to others.

Volatility (28): The share price moves around a lot.

Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TWST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TWST, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150$200Jan 26Apr 26Jul 26Oct 26TWSTHigh $212Median $118Low $36

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
9 Buy3 Hold1 Sell
Low $36Median $118High $212

The green dot is the last close — the median target sits −29.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
1 Oct 2026GuggenheimMaintainsBuy$107 → $212
29 Sept 2026Leerink PartnersMaintainsOutperform$160 → $190
18 Sept 2026BWS FinancialMaintainsSell$45
18 Sept 2026BWS FinancialMaintainsSell—
17 Sept 2026Leerink PartnersMaintainsOutperform—
17 Sept 2026Leerink PartnersMaintainsOutperform$120 → $160
9 Sept 2026BWS FinancialInitiatesSell—
9 Sept 2026BWS FinancialInitiatesSell$45
9 Sept 2026UBSInitiatesNeutral—
9 Sept 2026UBSInitiatesNeutral$144
5 Aug 2026Piper SandlerMaintainsOverweight$85 → $115
5 Aug 2026Piper SandlerMaintainsOverweight—
4 Aug 2026BairdMaintainsOutperform$113 → $115
4 Aug 2026BairdMaintainsOutperform—
14 July 2026Canaccord GenuityMaintainsBuy$90 → $120
14 July 2026Canaccord GenuityMaintainsBuy—
6 July 2026Evercore ISI GroupDowngradeIn-Line$66 → $102
6 July 2026Evercore ISI GroupDowngradeIn-Line—
29 June 2026GuggenheimMaintainsBuy$60 → $107
29 June 2026GuggenheimMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TWST appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TWST vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Twist Bioscience Corp. returned +424.2% against +16.6% for the S&P 500, dividends included.

TWST vs S&P 500, last 12 monthsTotal return, rebased to 100
0100200300400500600700Jan 26Apr 26Jul 26Oct 26TWSTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TWST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Twist Bioscience Corp. (TWST) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−157.7×

Cheaper than 99% of US stocks

Price / sales
31.5×

Cheaper than 7% of US stocks

Price / book
28.8×

Cheaper than 3% of US stocks

EV / EBITDA
−111.0×

Cheaper than 96% of US stocks

Growth & margins
Revenue growth (YoY)
23.2%

Higher than 72% of US stocks

Earnings growth (YoY)
23.2%

Higher than 61% of US stocks

Gross margin
52.8%

Higher than 65% of US stocks

Operating margin
−30.6%

Higher than 19% of US stocks

Net margin
−31.7%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−29.6%

Higher than 27% of US stocks

Return on assets
−13.1%

Higher than 24% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Twist Bioscience Corp. (TWST) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Twist Bioscience Corp. has a market value of $13.6B and an enterprise value of $12.8B.

  • Revenue in the twelve months to 30 June 2026: $431.8M. The latest quarter grew 23.2% year on year.

  • Net income over the same four quarters: −$136.7M, a −31.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.22.

  • Free cash flow in the twelve months to 30 June 2026: −$93.2M.

  • Twist Bioscience Corp. spent $18K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 62.7M.

  • Trailing P/E: −157.7×; forward P/E: −272.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Twist Bioscience Corp. employs 979 people — $441K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

TWST vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TWSTTwist Bioscience Corp.$13.6B
63
SMMTSummit Therapeutics, Inc.$13.8B
27
CORTCorcept Therapeutics, Inc.$13.1B
79
BBIOBridgeBio Pharma, Inc.$12.8B
65
JAZZJazz Pharmaceuticals Plc$14.8B
99
HALOHalozyme Therapeutics, Inc.$12.3B
97
EXELExelixis, Inc.$15.3B
98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Twist Bioscience Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TWST news & analysis

The Top HealthTech Questions Landing on Our Desks

ETF Trends · 30 Sept 2026neutral

ETF Trends reports that the healthtech sector has performed strongly over the past two quarters, drawing renewed market interest in medical innovation. In response to a high volume of inquiries, the publication compiled a guide answering frequent and notable questions about its Healthcare Technology and Innovation Index (HTEC).

Why it matters — A TWST watcher would care because the guide highlights growing investor attention and indexing interest in healthcare technology and innovation, a space in which Twist Bioscience participates.

Twist Bioscience Stock Hits New High, Then Retreats: What's Happening?

Benzinga · 25 Sept 2026neutral

Twist Bioscience Corp. shares retreated Friday after touching a fresh 52-week high near $192 earlier in the session. The stock pulled back from that intraday peak as trading progressed.

Why it matters — TWST watchers would care because the stock is hovering near a new 52-week high, a notable milestone for the company's recent share-price performance.

3 Analysts, 3 Trades to Make Today

InvestorPlace · 22 Sept 2026neutral

InvestorPlace published a piece titled "3 Analysts, 3 Trades to Make Today" in which an analyst referred to as Louis recommends buying the dip in AI-related stocks. The article does not specifically mention Twist Bioscience Corp.

Why it matters — A TWST watcher would note that the piece reflects analyst sentiment around AI-related equities, a sector in which Twist operates, though the article offers no explicit view on the company itself.

Why Twist Bioscience Stock Skyrocketed This Week

The Motley Fool · 18 Sept 2026positive

Twist Bioscience's stock rose sharply this week, following news that the biotech will both contribute to and draw from the findings of a program. The company will also earn revenue from its participation in the effort.

Why it matters — The stock's surge and the new revenue-generating program signal a potentially significant business development for Twist Bioscience watchers.

Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem

Benzinga · 16 Sept 2026positive

Twist Bioscience announced an agreement with Lilly TuneLab, Eli Lilly's collaborative AI/ML drug discovery platform. The agreement positions Twist in a data pipeline role within the TuneLab ecosystem.

Why it matters — A TWST watcher would care because this collaboration ties Twist's synthetic biology offerings into Eli Lilly's drug discovery platform, potentially expanding its commercial reach.

FAQ

Frequently asked questions about TWST stock

What is the TWST stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Twist Bioscience Corp. have a median 12-month price target of $118, with estimates ranging from $36 to $212. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TWST stock a buy right now?

Of the 13 analysts covering Twist Bioscience Corp., 9 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Twist Bioscience Corp. 63 out of 100 across roughly 4,600 US stocks as at 5 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TWST?

As at 5 Oct 2026, Twist Bioscience Corp. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will TWST stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies -29.6% from the last close, and Ticker Nerd's factor model ranks Twist Bioscience Corp. 63 out of 100 as at 5 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TWST stock forecast for 2030?

No analyst covering Twist Bioscience Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TWST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $212 over the next 12 months.

How has TWST stock performed over the past year?

Twist Bioscience Corp. returned +424.2% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Twist Bioscience Corp. do?

Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research.

What is the latest news on TWST?

The most recent item we track (ETF Trends, 30 Sept 2026): "The Top HealthTech Questions Landing on Our Desks". ETF Trends reports that the healthtech sector has performed strongly over the past two quarters, drawing renewed market interest in medical innovation. In response to a high volume of inquiries, the publication compiled a guide answering frequent and notable questions about its Healthcare Technology and Innovation Index (HTEC).

Company

About Twist Bioscience Corp.

Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research. The company also supports advanced workflows such as targeted next-generation sequencing, CRISPR gene editing, mutagenesis, and DNA data storage. Its proprietary semiconductor-based DNA synthesis platform is designed to produce high-quality synthetic DNA at scale, helping customers move from design to experimentation more efficiently. Twist Bioscience Corporation serves biotechnology, pharmaceutical, industrial, and academic customers across multiple regions, making it an important supplier in the life sciences tools and synthetic biology market.

CEO Dr. Emily Marine Leproust Ph.D. · 979 employees · United States · https://www.twistbioscience.com